Influenza

July 1st 2025

Vaccine candidate demonstrates 26.6% higher relative efficacy in adults 50 and older, with strong protection across flu strains.

June 12th 2025

Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.

June 11th 2025

The ongoing H5N1 avian flu outbreak has severely impacted U.S. poultry and dairy industries, prompting a $1 billion USDA response strategy that includes biosecurity, vaccination research, and innovation funding. With growing concern over viral mutations affecting humans and livestock, rapid, field-based diagnostic tools offer critical support in accelerating detection and containment efforts.

May 30th 2025

Despite the funding being terminated, the company said data from its phase 1/2 study of its investigational vaccine, mRNA-1018, demonstrated positive interim results.